GSK Sets Sights On ViiV HIV Spin-Out In 2016

CEO Andrew Witty said the company will explore the possibility of an IPO of a minority stake in ViiV, an HIV-centric joint venture with Pfizer and Shionogi, as the company continues to reshape its business.